http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
IMV Inc. Announces Second Quarter 2020 Financial Results
-
IMV Receives Funding From Canadian Governmental Agencies for COVID-19 Vaccine Phase 1 Clinical Study
-
IMV Inc. to Announce Second Quarter 2020 Results and Host a Conference Call and Webcast on August 12, 2020
-
IMV to Present at BTIG’s Virtual Biotechnology Conference
-
IMV Inc. (IMV) Announces Michael P. Bailey to Board
-
IMV Announces Appointment of Michael P. Bailey to Board of Directors
-
IMV Inc. (IMV) Updates Progress on COVID-19 Vaccine Program
-
IMV Updates Rapid Progress on COVID-19 Vaccine Program
-
IMV Files Preliminary Base Shelf Prospectus to Replace Expiring Base Shelf Prospectus
-
IMV Announces Leading Independent Proxy Advisory Firms Recommend Shareholders Vote FOR All Resolutions at Upcoming Annual and Special Meeting
-
IMV to Present at Raymond James' Human Health Innovation Conference
-
Clinical Response and Translational Data from DeCidE1, a Phase 2 Study of DPX-Survivac Immunotherapy in Patients with Advanced Recurrent Ovarian Cancer
-
IMV Inc. (IMV) Announces Selection of Vaccine Candidate Against COVID-19 to Advance Into Human Clinical Studies
-
IMV Announces Selection of a Vaccine Candidate Against COVID-19 to Advance Into Human Clinical Studies
-
IMV Inc. Provides Clinical and Operational Update and Announces First Quarter 2020 Financial Results
-
IMV Inc. to Announce First Quarter 2020 Results and Host a Conference Call and Webcast on May 15, 2020
-
Immunovaccine Announces Dosing of First Patient in Phase 1b Clinical Trial for DPX-Survivac in Combination With Incyte's IDO1 Enzyme Inhibitor Epacadostat
